WAIVER AGREEMENTWaiver Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
This Waiver Agreement, dated as of October 29, 2014 (the “Signing Date”), is by and between Purdue Pharma L.P., a Delaware limited partnership (“Purdue”), and Zogenix, Inc., a Delaware corporation (“Zogenix”). Purdue and Zogenix are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Supply Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
This First Amendment to the Commercial Supply Agreement (as defined below) (the "First Amendment") is made and entered into as of 12th day of September 2014 (“First Amendment Effective Date”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Collaboration and License Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations
UNIVERSITY HOSPITAL ANTWERP, having its offices at Wilrijkstraat 10, 2650 Edegem, Belgium, registered under company number 0874.619.603, and duly represented by Mr. Johnny Van der Straeten, Managing Director, who entrusts the execution of this Agreement to Prof. Dr. B. Ceulemans, Department of Neurology-Child Neurology, hereinafter referred to as "UZA",
AMENDMENT NO. 2 - DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 – DEVELOPMENT AND OPTION AGREEMENT (the “Amendment No. 2”) is made as of September 15th, 2014 (the “Amendment No. 2 Effective Date”), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada (“Altus”), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 USA (“Zogenix”). Each of Altus and Zogenix are sometimes referred to herein individually as a “Party” and together as the “Parties”.
THIRD AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
This Third Amendment to the License Agreement (as defined below) (the "Third Amendment") is made and entered into as of the 12th day of September 2014 (“Third Amendment Effective Date”).
